Clozapine impaired glucose-stimulated insulin secretion partly by increasing plasma 5-HT levels due to the inhibition of OCT1-mediated hepatic 5-HT uptake in mice
- PMID: 39472495
- PMCID: PMC11845781
- DOI: 10.1038/s41401-024-01401-w
Clozapine impaired glucose-stimulated insulin secretion partly by increasing plasma 5-HT levels due to the inhibition of OCT1-mediated hepatic 5-HT uptake in mice
Abstract
Patients taking atypical antipsychotics (AAPs), especially clozapine, are often associated with hyperglycaemia. Here, clozapine served as a representative agent for investigating how AAPs induce hyperglycaemia. In normal mice and mice fed a high fat diet (HFD), clozapine impaired glucose tolerance and glucose-stimulated insulin secretion (GSIS) following intraperitoneal glucose administration and increased plasma 5-HT levels. Intraperitoneal 5-HT administration also impaired glucose tolerance and GSIS in mice. In INS-1 cells, high 5-HT levels impaired GSIS, which was attenuated by the 5-HTR3 antagonist tropisetron or by silencing 5-HTR3a. The 5-HTR2a agonist TCB2 attenuated clozapine-induced GSIS impairment. Silencing 5-HTR2a or the 5-HTR2a antagonist ketanserin impaired GSIS. In mice, 5-HT administration impaired GSIS, which was attenuated by tropisetron but aggravated by clozapine. Clozapine increased plasma [2H]5-HT exposure following intravenous administration to mice. In HEK293-OCT1 cells, clozapine inhibited [2H]5-HT and MPP+ uptake. Clozapine or OCT1 silencing impaired 5-HT metabolism in mouse primary hepatocytes, demonstrating that clozapine increased plasma 5-HT levels via the inhibition of OCT1-mediated hepatic 5-HT uptake. Liver-specific silencing of OCT1 increased plasma [2H]5-HT exposure and 5-HT levels and impaired GSIS and glucose tolerance in mice. In conclusion, clozapine impaired GSIS and glucose tolerance by increasing plasma 5-HT levels via the inhibition of OCT1-mediated hepatic 5-HT uptake. Increased 5-HT impaired GSIS by activating islet 5-HTR3a. The antagonistic effect of clozapine on islet 5-HTR2a also contributed to GSIS impairment. The finding that clozapine-induced GSIS impairment was attributed to increased 5-HT levels via the inhibition of OCT1-mediated hepatic 5-HT uptake may partly explain hyperglycaemia caused by other AAPs.
Keywords: 5-HT; atypical antipsychotics; clozapine; glucose intolerance; glucose-stimulated insulin secretion; organic cation transporter-1.
© 2024. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society.
Conflict of interest statement
Competing interests: The authors declare no competing interests.
Similar articles
-
METRNL represses beta-to-alpha cell trans-differentiation to maintain beta cell function under diabetic metabolic stress in mice.Diabetologia. 2025 Aug;68(8):1769-1788. doi: 10.1007/s00125-025-06459-7. Epub 2025 Jun 10. Diabetologia. 2025. PMID: 40495021
-
Combined Deletion of Slc30a7 and Slc30a8 Unmasks a Critical Role for ZnT8 in Glucose-Stimulated Insulin Secretion.Endocrinology. 2016 Dec;157(12):4534-4541. doi: 10.1210/en.2016-1573. Epub 2016 Oct 18. Endocrinology. 2016. PMID: 27754787 Free PMC article.
-
Gut-specific Neprilysin Deletion Protects Against Fat-induced Insulin Secretory Dysfunction in Male Mice.Endocrinology. 2024 Jul 1;165(8):bqae080. doi: 10.1210/endocr/bqae080. Endocrinology. 2024. PMID: 38953181 Free PMC article.
-
Risperidone versus other atypical antipsychotics for schizophrenia.Cochrane Database Syst Rev. 2011 Jan 19;2011(1):CD006626. doi: 10.1002/14651858.CD006626.pub2. Cochrane Database Syst Rev. 2011. PMID: 21249678 Free PMC article.
-
Olanzapine versus other atypical antipsychotics for schizophrenia.Cochrane Database Syst Rev. 2010 Mar 17;2010(3):CD006654. doi: 10.1002/14651858.CD006654.pub2. Cochrane Database Syst Rev. 2010. PMID: 20238348 Free PMC article.
References
-
- Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs. 2002;16:77–89. - PubMed
-
- Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab. 2007;33:169–75. - PubMed
-
- Cernea S, Dima L, Correll CU, Manu P. Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics. Drugs. 2020;80:1763–81. - PubMed
-
- Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64–77. - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources